What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?
Scheiman
James M
JM
Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109-0362, USA. jscheima@med.umich.edu
D000328:Adult; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007410:Intestinal Diseases / Q000139:chemically induced* / Q000201:enzymology / Q000473:pathology; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007421:Intestine, Small / Q000187:drug effects* / Q000473:pathology; D009288:Naproxen / Q000009:adverse effects; D009853:Omeprazole / Q000009:adverse effects; D011446:Prospective Studies; D011720:Pyrazoles / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects
D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D009288:Naproxen; D000068579:Celecoxib; D009853:Omeprazole